132 related articles for article (PubMed ID: 8847559)
1. Intra-arterial cisplatin in malignant brain tumors: incidence and severity of otic toxicity.
Assietti R; Olson JJ
J Neurooncol; 1996 Mar; 27(3):251-8. PubMed ID: 8847559
[TBL] [Abstract][Full Text] [Related]
2. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
3. Intra-arterial cisplatin for the treatment of malignant gliomas.
Newton HB; Page MA; Junck L; Greenberg HS
J Neurooncol; 1989 May; 7(1):39-45. PubMed ID: 2547032
[TBL] [Abstract][Full Text] [Related]
4. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
[TBL] [Abstract][Full Text] [Related]
5. Profound hearing loss from intravertebral artery cisplatin.
Wetmore SJ; Koike KJ; Bloomfield SM
Otolaryngol Head Neck Surg; 1997 Feb; 116(2):234-7. PubMed ID: 9051071
[No Abstract] [Full Text] [Related]
6. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
Haugnes HS; Stenklev NC; Brydøy M; Dahl O; Wilsgaard T; Laukli E; Fosså SD
Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
[TBL] [Abstract][Full Text] [Related]
7. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
Schmidt CM; Bartholomäus E; Deuster D; Heinecke A; Dinnesen AG
HNO; 2007 Apr; 55(4):299-306. PubMed ID: 16437215
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer.
Ishikawa E; Sugimoto H; Hatano M; Nakanishi Y; Tsuji A; Endo K; Kondo S; Wakisaka N; Murono S; Ito M; Yoshizaki T
Acta Otolaryngol; 2015 Sep; 135(9):919-24. PubMed ID: 25861690
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients.
Viglietta V; Shi F; Hu QY; Ren Y; Keilty J; Wolff H; McCarthy R; Kropp J; Weber P; Soglia J
Invest New Drugs; 2020 Oct; 38(5):1463-1471. PubMed ID: 32157599
[TBL] [Abstract][Full Text] [Related]
10. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors.
Tfayli A; Hentschel P; Madajewicz S; Manzione J; Chowhan N; Davis R; Roche P; Iliya A; Roque C; Meek A; Shady M
J Neurooncol; 1999 Mar; 42(1):73-7. PubMed ID: 10360481
[TBL] [Abstract][Full Text] [Related]
11. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach.
Orgel E; Jain S; Ji L; Pollick L; Si S; Finlay J; Freyer DR
Pediatr Blood Cancer; 2012 Jun; 58(6):953-8. PubMed ID: 21796767
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas.
Dropcho EJ; Rosenfeld SS; Vitek J; Guthrie BL; Morawetz RB
J Neurooncol; 1998 Jan; 36(2):191-8. PubMed ID: 9525819
[TBL] [Abstract][Full Text] [Related]
13. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
14. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer.
Balm AJ; Rasch CR; Schornagel JH; Hilgers FJ; Keus RB; Schultze-Kool L; Ackerstaff AH; Busschers W; Tan IB
Head Neck; 2004 Jun; 26(6):485-93. PubMed ID: 15162349
[TBL] [Abstract][Full Text] [Related]
15. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA
Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183
[TBL] [Abstract][Full Text] [Related]
16. Intra-arterial cisplatin--associated optic and otic toxicity.
Maiese K; Walker RW; Gargan R; Victor JD
Arch Neurol; 1992 Jan; 49(1):83-6. PubMed ID: 1728268
[TBL] [Abstract][Full Text] [Related]
17. Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation.
Bobo H; Kapp JP; Vance R
J Neurooncol; 1992 Jul; 13(3):291-9. PubMed ID: 1517805
[TBL] [Abstract][Full Text] [Related]
18. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ
Oncology; 2017; 93(2):75-82. PubMed ID: 28511189
[TBL] [Abstract][Full Text] [Related]
19. Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto- and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiency.
Dósa E; Heltai K; Radovits T; Molnár G; Kapocsi J; Merkely B; Fu R; Doolittle ND; Tóth GB; Urdang Z; Neuwelt EA
Fluids Barriers CNS; 2017 Oct; 14(1):26. PubMed ID: 28974245
[TBL] [Abstract][Full Text] [Related]
20. Ocular and orbital complications of intraarterial cisplatin. A case report.
Wu HM; Lee AG; Lehane DE; Chi TL; Lewis RA
J Neuroophthalmol; 1997 Sep; 17(3):195-8. PubMed ID: 9304534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
